CA2734769A1 - Use of d-ribose for fatigued subjects - Google Patents
Use of d-ribose for fatigued subjects Download PDFInfo
- Publication number
- CA2734769A1 CA2734769A1 CA2734769A CA2734769A CA2734769A1 CA 2734769 A1 CA2734769 A1 CA 2734769A1 CA 2734769 A CA2734769 A CA 2734769A CA 2734769 A CA2734769 A CA 2734769A CA 2734769 A1 CA2734769 A1 CA 2734769A1
- Authority
- CA
- Canada
- Prior art keywords
- ribose
- effective amount
- fatigue
- subjects
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title claims abstract description 79
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 38
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 38
- 206010016256 fatigue Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 230000003340 mental effect Effects 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 208000016255 tiredness Diseases 0.000 claims description 4
- 230000003867 tiredness Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 206010024264 Lethargy Diseases 0.000 claims description 2
- 206010041349 Somnolence Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000002996 emotional effect Effects 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 206010025482 malaise Diseases 0.000 claims description 2
- 235000017802 other dietary supplement Nutrition 0.000 claims description 2
- 230000036642 wellbeing Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 abstract description 12
- 230000002612 cardiopulmonary effect Effects 0.000 abstract description 3
- 230000008447 perception Effects 0.000 abstract description 2
- 230000006996 mental state Effects 0.000 abstract 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 22
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 15
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 9
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 8
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 230000000276 sedentary effect Effects 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000004145 nucleotide salvage Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- -1 pentose carbohydrate Chemical class 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18949808P | 2008-08-20 | 2008-08-20 | |
| US61/189,498 | 2008-08-20 | ||
| US20812209P | 2009-02-20 | 2009-02-20 | |
| US61/208,122 | 2009-02-20 | ||
| PCT/US2009/004738 WO2010021713A1 (en) | 2008-08-20 | 2009-08-20 | Use of d-ribose for fatigued subjects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2734769A1 true CA2734769A1 (en) | 2010-02-25 |
Family
ID=41172394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2734769A Abandoned CA2734769A1 (en) | 2008-08-20 | 2009-08-20 | Use of d-ribose for fatigued subjects |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100189785A1 (enExample) |
| EP (1) | EP2323668A1 (enExample) |
| JP (2) | JP2012500261A (enExample) |
| CN (2) | CN105232564A (enExample) |
| AU (1) | AU2009283215B2 (enExample) |
| BR (1) | BRPI0917360A2 (enExample) |
| CA (1) | CA2734769A1 (enExample) |
| WO (1) | WO2010021713A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2757442A1 (en) * | 2008-04-02 | 2009-10-08 | Bioenergy, Inc. | Use of ribose in first response to acute myocardial infarction |
| CN102488669A (zh) * | 2011-12-30 | 2012-06-13 | 上海希迪制药有限公司 | 一种改善d-核糖引湿性的方法 |
| CA2966628C (en) * | 2014-11-03 | 2023-08-29 | Bioenergy Life Science, Inc. | Use of d-ribose to enhance adaptation to physical stress |
| WO2017120731A1 (en) * | 2016-01-11 | 2017-07-20 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Methods and compositions for reducing body weight |
| JP6542687B2 (ja) | 2016-01-28 | 2019-07-10 | 日本特殊陶業株式会社 | ガスセンサユニット |
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US20190313682A1 (en) * | 2018-04-12 | 2019-10-17 | Metabolic Recovery Systems, LLC | Compositions and methods for supplementing the diet |
| WO2020041750A1 (en) * | 2018-08-24 | 2020-02-27 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Methods and compositions for treating disorders associated with muscle weakness |
| KR102435548B1 (ko) * | 2022-05-31 | 2022-08-26 | (주)에이피테크놀로지 | 액상스틱형 에너지 스포츠 음료 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4228215A1 (de) * | 1992-08-25 | 1994-03-03 | Pliml Wolfgang | Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen |
| EP1745789A1 (en) * | 1998-06-19 | 2007-01-24 | Bioenergy Inc. | Compositions comprising ribose for increasing energy in vivo |
| US6159942A (en) * | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
| US6159943A (en) * | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
| CA2325033C (en) * | 1999-10-27 | 2007-05-22 | Bioenergy Inc. | Use of ribose to treat fibromyalgia |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| IT1317043B1 (it) * | 2000-06-14 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio. |
| US6855727B2 (en) * | 2000-12-04 | 2005-02-15 | Yaizu Suisankagaku Industry Co., Ltd. | Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect |
| US20070191287A1 (en) * | 2004-03-18 | 2007-08-16 | Michio Yamamura | D-ribose for improving depression-like symptoms |
| ES2393786T3 (es) * | 2004-04-29 | 2012-12-28 | Ribocor, Inc. | Método para mejorar la eficacia ventilatoria |
| US20100099630A1 (en) * | 2004-04-29 | 2010-04-22 | Maccarter Dean J | Method for improving ventilatory efficiency |
| US7645742B2 (en) * | 2005-06-22 | 2010-01-12 | Advocare International, L.P. | Composition for enhancing cellular energy |
| WO2022123637A1 (ja) | 2020-12-07 | 2022-06-16 | 株式会社日立製作所 | 文書処理システムおよび文書処理方法 |
-
2009
- 2009-08-20 CN CN201510527242.0A patent/CN105232564A/zh active Pending
- 2009-08-20 JP JP2011523814A patent/JP2012500261A/ja not_active Withdrawn
- 2009-08-20 US US12/583,430 patent/US20100189785A1/en not_active Abandoned
- 2009-08-20 CA CA2734769A patent/CA2734769A1/en not_active Abandoned
- 2009-08-20 AU AU2009283215A patent/AU2009283215B2/en active Active
- 2009-08-20 CN CN2009801324503A patent/CN102215846A/zh active Pending
- 2009-08-20 WO PCT/US2009/004738 patent/WO2010021713A1/en not_active Ceased
- 2009-08-20 BR BRPI0917360A patent/BRPI0917360A2/pt not_active Application Discontinuation
- 2009-08-20 EP EP09789171A patent/EP2323668A1/en not_active Withdrawn
-
2012
- 2012-04-11 US US13/444,279 patent/US20120264701A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015095225A patent/JP2016014009A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009283215A2 (en) | 2011-05-12 |
| AU2009283215B2 (en) | 2014-12-04 |
| AU2009283215A1 (en) | 2010-02-25 |
| EP2323668A1 (en) | 2011-05-25 |
| JP2012500261A (ja) | 2012-01-05 |
| US20100189785A1 (en) | 2010-07-29 |
| BRPI0917360A2 (pt) | 2015-11-17 |
| WO2010021713A1 (en) | 2010-02-25 |
| CN102215846A (zh) | 2011-10-12 |
| CN105232564A (zh) | 2016-01-13 |
| US20120264701A1 (en) | 2012-10-18 |
| JP2016014009A (ja) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009283215B2 (en) | Use of D-ribose for fatigued subjects | |
| EP1087779B1 (en) | Compositions for increasing energy in vivo | |
| Flores et al. | Shorter sprints elicit greater cardiorespiratory and mechanical responses with less fatigue during time-matched sprint interval training (SIT) sessions | |
| KR20110135986A (ko) | 당뇨병 요법을 지원하기 위한 α-케토산을 포함하는 식이 보충제 | |
| Do Amaral et al. | The effect of acute magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary disease patients | |
| Turley et al. | Effects of caffeine on anaerobic exercise in boys | |
| WO2014155186A1 (es) | Complemento alimenticio para personas con trisomia 21, trastorno del espectro autista y/o trastorno por déficit de atención con o sin hiperactividad | |
| US20160317561A1 (en) | Use of d-ribose for fatigued subjects | |
| Aktaş et al. | Six weeks of time-restricted eating improves basal fat oxidation and body composition but not fat oxidation during exercise in young males | |
| D BELBIS et al. | The effects of acute caffeine supplementation on repeated-sprint ability in healthy young non-athletes | |
| Alis | The effects of a coconut beverage on blood glucose and lactate concentrations | |
| EP1745789A1 (en) | Compositions comprising ribose for increasing energy in vivo | |
| Shidqi et al. | The impact of drinking brewed coffee on VO2max and blood lactate levels in sedentary males with physical activity treatment | |
| Kotarsky et al. | Impact of MCT Oil and Caffeine on Substrate Metabolism during Submaximal Exercise | |
| Durak et al. | A Case Report Using High Intensity Interval Training (HIIT) Resistive Exercise and Subsequent Changes in Body Fat and Metabolic Health Markers in an Unconditioned Female | |
| Szabóová et al. | Can the Regular Physical Load Change the Functional State of Pupils in Elementary School? | |
| Roelofs | Effects of pomegranate extract on anaerobic exercise performance & cardiovascular responses | |
| Prins | The effect of energy drink ingestion on 5-km running performance in recreational endurance runners | |
| Jones | THE INFLUENCE OF A HIGH-NITRATE BEVERAGE ON THE RATE OF FORCE DEVELOPMENT AND PEAK FORCE OUTPUT OF COLLEGE-AGED INDIVIDUALS DURING AN ISOMETRIC MID-THIGH PULL | |
| Petteys | The effect of pre exercise feeding on endurance performance | |
| Nelson | The long-term effects of pre-workout supplementation on resting energy expenditure and body composition in recreationally active females | |
| Choi | The effects of thiamine on anti-fatigue during exercise | |
| Derosier | The effects of varying postexercise nutrition on subsequent exercise performance in active adults habitually consuming a low-carbohydrate/high-fat diet | |
| Born | The Effect of Creatine Supplementation on Exercise Performance following a Short-term Low Carbohydrate Diet | |
| WO2009013723A2 (en) | Ethyl pyruvate alone or in combination with mi cro- clustered water and use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140501 |
|
| FZDE | Dead |
Effective date: 20180918 |